Defactinib - Moligand™, 2mM in DMSO , CAS No.1073154-85-4

CAS: 1073154-85-4 Cat. No.: D420521 Formule: C20H21F3N8O3S Poids moléculaire: 510.49 Numéro CE: 969-109-7
DISPONIBLE À COMMANDE
QUALITÉ & PURETÉ Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 2mM in DMSO
Synonyms
Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-|N-methyl-4-((4-(((3-methyl(methylsulfonyl)aminopyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide|VS 6063|PF 04554878|SDCCGSBI-0051230.P002|N-Methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide|N-methyl-4-((4-(((3-(N-methylmethylsulfonamido)pyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide|4-(Aminomethyl)-Cyclohexanecarboxylic Acid|DEFACTINIB [WHO-DD]|PF-04554878|Defactinib [USAN]|Defactinib (VS-6063, PF-04554878)|DEFACTINIB [INN]|Defactinib [USAN:INN]|Defactinib|N-methyl-4-({4-[({3- [methyl(methylsulfonyl)amino]pyrazin-2- yl}methyl)amino]-5- (trifluoromethyl)pyrimidin-2- yl}amino)benzamide (317)|N-methyl-4-(4-((3-(N-methylmethylsulfonamido)pyrazin-2-yl)methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)benzamide|Defactinib (USAN/INN)
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Taille
Allemagne (EU)
USA*
Prix
Qté
1ml
D420521-1ml
Sur commande · 8–12 semaines

51,11€

60,65€
Enregistrer 9,55 € (15.74%)
Enter a quantity for the sizes you want to add.

Vue d’ensemble

Shipped at Room Temperature. Store at -20°C. Store under desiccating conditions.

Spécifications

Synonymes
Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)- | N-methyl-4-((4-(((3-methyl(methylsulfonyl)aminopyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide | VS 6063 | PF 04554878 | SDCCGSBI-0051230.P002 | N-Methyl-4-((4-(((3-(methyl(methyls Afficher plus
Spécifications et pureté
Moligand™, 2mM in DMSO
Mécanismes biochimiques et physiologiques
Potent FAK\xa0inhibitor. Prevents tumor invasion and dissemination. Preferentially targets cancer stem cells in mouse xenograft models. Orally bioavailable.
Conditions de stockage de stockage
Store at -80°C
Expédié en
Dry ice packs + Cold packs
Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.
Grade
Moligand™
Propriétés du produit
ALogP
1.4
Noms et identifiants
SMILES
CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F
IUPAC Name
N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide
InChIKey
FWLMVFUGMHIOAA-UHFFFAOYSA-N
InChI
1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)
Isomères SMILES
CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F
CAS alternatif
1073154-85-4
Termes d'entrée MeSH
defactinib;N-methyl-4-((4-(((3-methyl(methylsulfonyl)aminopyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide;PF-04554878;VS-6063
Poids moléculaire
510.49
Reaxy-Rn
18939458
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=18939458&ln=

Données avancées

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassBenzenoids
ClasseBenzene and substituted derivatives
SubclassBenzoic acids and derivatives
Intermediate Tree Nodes Not available
Direct ParentBenzamides
Alternative Parents Aniline and substituted anilines  Benzoyl derivatives  Aminopyrimidines and derivatives  Secondary alkylarylamines  Pyrazines  Organosulfonamides  Imidolactams  Organic sulfonamides  Heteroaromatic compounds  Aminosulfonyl compounds  Secondary carboxylic acid amides  Amino acids and derivatives  Azacyclic compounds  Organic oxides  Hydrocarbon derivatives  Alkyl fluorides  Organofluorides  Organooxygen compounds  Organopnictogen compounds  
Molecular FrameworkAromatic heteromonocyclic compounds
Substituents Benzamide - Benzoyl - Aniline or substituted anilines - Secondary aliphatic/aromatic amine - Aminopyrimidine - Organic sulfonic acid amide - Organosulfonic acid amide - Pyrazine - Pyrimidine - Imidolactam - Organic sulfonic acid or derivatives - Organosulfonic acid or derivatives - Heteroaromatic compound - Aminosulfonyl compound - Sulfonyl - Amino acid or derivatives - Carboxamide group - Secondary carboxylic acid amide - Carboxylic acid derivative - Azacycle - Organoheterocyclic compound - Secondary amine - Organooxygen compound - Organonitrogen compound - Organofluoride - Organohalogen compound - Alkyl fluoride - Hydrocarbon derivative - Organic oxide - Organopnictogen compound - Organic oxygen compound - Organosulfur compound - Alkyl halide - Amine - Organic nitrogen compound - Aromatic heteromonocyclic compound
DescriptionThis compound belongs to the class of organic compounds known as benzamides. These are organic compounds containing a carboxamido substituent attached to a benzene ring.
External Descriptors Not available
Structure 3D
Modèle de structure chimique interactif





Cibles associées (humaines)
PTK2 Tclin Focal adhesion kinase 1 (5 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CDKL5 Tchem Cyclin-dependent kinase-like 5 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
NTRK1 Tclin High affinity nerve growth factor receptor (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
JAK2 Tclin Tyrosine-protein kinase JAK2 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ABL1 Tclin Tyrosine-protein kinase ABL (18331 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
INSR Tclin Insulin receptor (5558 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRB2 Tclin Beta-2 adrenergic receptor (11824 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRB1 Tclin Beta-1 adrenergic receptor (6630 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TOP2A Tclin DNA topoisomerase II alpha (6317 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD2 Tclin Dopamine D2 receptor (23596 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD1 Tclin Dopamine D1 receptor (9720 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD4 Tchem Dopamine D4 receptor (7907 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A2 Tclin Norepinephrine transporter (10102 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HRH2 Tclin Histamine H2 receptor (5428 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1D Tclin Alpha-1d adrenergic receptor (4171 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1D Tclin Serotonin 1d (5-HT1d) receptor (2897 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1B Tclin Serotonin 1b (5-HT1b) receptor (2801 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A4 Tclin Serotonin transporter (12625 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HRH1 Tclin Histamine H1 receptor (7573 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1B Tclin Alpha-1b adrenergic receptor (2912 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRM1 Tclin Mu opioid receptor (19785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD3 Tclin Dopamine D3 receptor (14368 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRD1 Tclin Delta opioid receptor (15096 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRK1 Tclin Kappa opioid receptor (16155 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR3A Tclin Serotonin 3a (5-HT3a) receptor (3366 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A3 Tclin Dopamine transporter (10535 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDGFRB Tclin Platelet-derived growth factor receptor beta (5195 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM4 Tclin Muscarinic acetylcholine receptor M4 (6041 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM5 Tclin Muscarinic acetylcholine receptor M5 (4677 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA2B Tclin Alpha-2b adrenergic receptor (4412 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA2C Tclin Alpha-2c adrenergic receptor (4876 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM3 Tclin Muscarinic acetylcholine receptor M3 (7750 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD5 Tchem Dopamine D5 receptor (1597 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRB3 Tclin Beta-3 adrenergic receptor (5850 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2B Tclin Serotonin 2b (5-HT2b) receptor (10323 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
IGF1R Tclin Insulin-like growth factor I receptor (8605 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KIT Tclin Stem cell growth factor receptor (10667 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA2A Tclin Adenosine A2a receptor (16305 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA3 Tchem Adenosine A3 receptor (15931 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CSNK2A1 Tchem Casein kinase II alpha (3512 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DAPK3 Tchem Death-associated protein kinase 3 (2108 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DCK Tchem Deoxycytidine kinase (530 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAPK11 Tchem MAP kinase p38 beta (2785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
LCK Tclin Tyrosine-protein kinase LCK (9212 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NQO2 Tchem Quinone reductase 2 (885 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cibles associées (non humaines)
Cdk4 Cyclin-dependent kinase 4 (3 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Htr7 Serotonin 7 (5-HT7) receptor (19 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Sigmar1 Sigma opioid receptor (160 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hrh4 Histamine H4 receptor (388 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIK3CA PI3-kinase p110-alpha subunit (51 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Pygl Liver glycogen phosphorylase (81 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Prkcd Protein kinase C delta (192 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Prkcb Protein kinase C beta (2 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mapk1 MAP kinase ERK2 (650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Fgfr4 Fibroblast growth factor receptor 4 (138 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Fgfr3 Fibroblast growth factor receptor 3 (21 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Camk2g CaM kinase II gamma (1 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Tec Tyrosine-protein kinase TEC (25 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AIRC Multifunctional protein ADE2 (8 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Gabrp GABA-A receptor; anion channel (5731 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
pknB Serine/threonine-protein kinase pknB (356 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CDPK1 Calcium-dependent protein kinase 1 (793 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CRK2 Cell division control protein 2 homolog (194 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Septin9 Septin-9 (1 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Acadvl Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (1 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Tmem97 Sigma intracellular receptor 2 (922 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mécanismes d'action
Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Propriétés chimiques et physiques
Poids moléculaire510.500 g/mol
XLogP31.400
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count13
Rotatable Bond Count8
Exact Mass510.141 Da
Monoisotopic Mass510.141 Da
Topological Polar Surface Area150.000 Ų
Heavy Atom Count35
Formal Charge0
Complexity804.000
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds0
Covalently-Bonded Unit Count1
FAQ et articles
Citations of This Product
Calculateurs de solution
Avis

Avis des clients

Application Protocols

Application-validated protocols and recommended dilutions are not provided in the Product Data for this SKU.

General starting points (literature/common practice; adjust to your system):

  • Biochemical kinase assay:
    • Prepare a 10 mM DMSO stock. Perform serial dilutions to achieve 10‑point concentration–response (e.g., 0.1 nM–10 µM). Preincubate inhibitor with kinase (e.g., 15–30 min) before initiating reaction with ATP/substrate.
  • Cell-based assay:
    • Dilute DMSO stock into culture medium to desired concentrations (typical 10 nM–3 µM). Keep final DMSO ≤0.1–0.5% v/v. Assess pathway markers (e.g., phospho‑FAK levels) after 1–24 h.
  • Data analysis:
    • Fit normalized responses to a four-parameter logistic model to estimate IC50/EC50; include at least three biological replicates.

These are generic guidelines for small-molecule kinase probes and should be validated and optimized for your specific assay. For item-specific protocols, consult the CoA/Spec Sheet or contact Aladdin Scientific.

Biological Roles

Defactinib is widely referenced in the literature as a small-molecule inhibitor used to interrogate focal adhesion signaling.

  • Primary target (literature/general): Focal adhesion kinase (FAK, gene PTK2), a non-receptor tyrosine kinase central to integrin signaling, cytoskeletal dynamics, and mechanotransduction.
  • Pathway context (literature/general):
    • FAK autophosphorylation at Tyr397 recruits Src-family kinases and scaffolding proteins, coordinating focal adhesion assembly/disassembly.
    • Crosstalk with PI3K/AKT, MAPK/ERK, and Hippo/YAP–TAZ pathways influences cell adhesion, migration, survival, and mechanosensitive gene expression.
  • Research applications:
    • Dissection of adhesion-dependent signaling, epithelial–mesenchymal transition markers, and migration/invasion phenotypes in cellular models.
    • Benchmarking selectivity versus PYK2 (PTK2B) and broader kinome panels.
  • Biophysical/biochemical considerations (general):
    • ATP-competitive binding is commonly reported for FAK-directed chemotypes; binding engages hinge-region H-bonding and hydrophobic pockets. Actual binding kinetics/thermodynamics are assay- and lot-dependent; confirm experimentally with enzyme assays or cellular phospho‑FAK readouts.

Important note: All statements above reflect general literature knowledge about this chemotype’s research use. No medical or clinical claims are made; this product is for research use only as stated by the manufacturer.

Buffer Applications

This compound is not a buffering agent and is not used to control solution pH.

Practical notes for assay buffers (general):

  • Prepare working solutions by diluting DMSO stocks into biologically compatible buffers (e.g., PBS, HEPES, or assay‑specific kinase reaction buffers) while keeping final DMSO low (≤0.1–0.5% v/v) to maintain cell viability and enzyme activity.
  • Include carrier proteins (e.g., 0.1–0.5% BSA) or mild non-ionic surfactants if adsorption or precipitation is observed; validate compatibility with the assay readout.

Buffer specifications (pH, composition, ionic strength) are dictated by the biological assay rather than by the compound; follow your validated protocol.

Green Alternatives

As a solid bioactive ligand used at micromolar concentrations, the principal environmental considerations are solvent choice, dilution media, and waste minimization rather than replacement of the active itself.

Greener handling strategies (general):

  • Stock solvent optimization:
    • Use the minimal DMSO concentration necessary for solubility; consider preparing higher‑concentration master stocks to reduce total DMSO volume introduced into assays and waste streams.
  • Aqueous formulations:
    • Where feasible, incorporate biodegradable surfactants at very low levels to aid dispersion, minimizing organic cosolvent requirements.
  • Waste reduction:
    • Consolidate and segregate DMSO- and acetonitrile-containing waste for energy-efficient disposal.
  • Packaging and throughput:
    • Opt for pre-aliquoted, single‑use vials or microplates to reduce freeze–thaw cycles and material loss, lowering overall solvent consumption.

Comparison of common stock solvents (general):

  • DMSO: High solvency; readily biodegradable but can increase COD in effluent—collect as hazardous waste.
  • Ethanol/water cosolvent systems: Greener profile; may not achieve necessary solubility.
  • 2‑MeTHF/CPME: Greener for synthesis workflows but rarely appropriate for bioassay stocks.

Item-specific environmental attributes: Not specified for this item; refer to SDS and institutional green chemistry guidelines.

Pharmaceutical Uses

This material is provided strictly for research use only and is not formulated to any pharmacopeial standard.

  • Typical roles in pharmaceutical R&D (non-clinical, literature/general):
    • Reference standard or tool compound for target engagement assays, SAR benchmarking, and PK/PD method development in preclinical research settings.
    • Positive control for biochemical and cellular assays probing focal adhesion kinase pathways.
  • Regulatory/compendial status for this catalog item: Not specified; this product is not supplied under GMP and is not intended for human or veterinary use.
  • Excipients, dosage forms, impurity limits: Not specified for this item; refer to CoA/Spec Sheet if any auxiliary materials are present.

Do not use in diagnostic, therapeutic, or clinical applications. For regulated use or GMP-grade requests, contact Aladdin Scientific for potential custom manufacturing and documentation options.

Physical Properties

Item-specific physicochemical specifications (for QC release) are not provided in the Product Data.

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point, boiling point, density, refractive index, UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.

General/literature handling-relevant properties (qualitative, for planning only):

  • Physical state: Typically an off-white to light-colored solid in many reports of similar kinase inhibitors (literature/general). Actual appearance may vary by lot.
  • Solubility profile (literature/general):
    • Highly soluble in polar aprotic organic solvents such as DMSO and DMF.
    • Limited solubility in aqueous buffers without cosolvent or solubilizing excipients; aqueous stocks are usually prepared by diluting a DMSO master stock.
  • Partitioning: Kinase inhibitors of this class often display moderate-to-high lipophilicity (logP/logD in the mid range), which guides the need for DMSO stocks and careful dilution to avoid precipitation; confirm with item-specific data before use.

Important: Treat all non-specified numerical properties as Not specified for this item; refer to CoA/Spec Sheet and SDS for authoritative values.

Quality and Grades
  • Grade/Purity: Moligand™
    • Moligand™ indicates the material is curated for small‑molecule discovery, screening, and chemical biology workflows. Emphasis is placed on identity confirmation and suitability for assay use rather than application-specific solvent specifications (e.g., LC/MS grade solvents) or trace metal minima used for catalysis reagents.
    • Typical expectations for Moligand™ items (general): Verified identity (e.g., NMR/LC–MS), purity commensurate with screening use, and packaging that supports long-term low‑temperature storage.

What this means for your experiments:

  • Analytical traceables: For orthogonal confirmation (e.g., retention time and mass), request or consult the CoA/Spec Sheet. Do not assume HPLC-UV cutoff, residual solvent profile, water content, or metal assay values unless provided.
  • Stabilizers: Not specified for this item; refer to CoA/Spec Sheet. If a stabilizer is present, account for it in mass balance and biological assay interpretation.
  • Lot-to-lot reproducibility: Moligand™ curation favors consistent performance in standardized dilution protocols (DMSO master stock → buffered assay media). Nonetheless, verify activity in-house with positive/negative controls upon receipt of a new lot.

If you require alternate formats (e.g., salt form, control analogs, pre-weighed plates, or QC thresholds tailored to your platform), contact Aladdin Scientific to discuss custom preparation and documentation.

Reaction and Applications

This product is supplied as a bioactive small-molecule ligand for research and screening; it is not typically employed as a stoichiometric reagent or solvent in synthetic transformations.

Research applications (literature/general):

  • Chemical biology probe for focal adhesion kinase (FAK/PTK2) pathway interrogation in cell-based and biochemical assays.
  • Tool compound in studies of focal adhesion signaling, cytoskeletal dynamics, mechanotransduction, and YAP/TAZ pathway readouts.
  • Reference control in kinase panel profiling and selectivity benchmarking.

Assay implementation tips:

  • Prepare concentrated DMSO stocks (e.g., 10–50 mM); filter through 0.22 µm PTFE if particulate forms.
  • Use serial dilutions to construct concentration–response curves; typical ranges span low nM to low µM depending on assay sensitivity and protein binding.
  • Include a vehicle control (matching DMSO %) and orthogonal readouts (e.g., biochemical kinase assay plus cell phospho‑marker assay) to validate on‑target effects.

Chemical reactivity considerations:

  • Kinase inhibitors of this class can be sensitive to strong acids/bases and oxidants; avoid harsh conditions. Light and moisture protection may improve stability of DMSO stocks.

If you require a derivatizable analog or functional handle (e.g., alkyne/azide/biotin) for chemoproteomics or imaging, contact us for custom synthesis—this catalog item is provided as the unmodified ligand.

Reaction Conditions

Not typically applicable: this product is a bioactive ligand supplied for biological and screening assays, not a reagent for chemical reactions.

Experimental conditions relevant to biological assays (literature/general):

  • Stock preparation: Dissolve in anhydrous DMSO at 10–50 mM; vortex and, if needed, warm gently (≤37 °C) to aid dissolution. Avoid prolonged heating.
  • Working concentrations: Frequently in the low‑nM to low‑µM range depending on assay sensitivity, protein binding, and cell permeability. Establish concentration–response curves (e.g., 10‑point, 3‑fold serial dilutions).
  • Incubation: 15–60 min preincubation for biochemical kinase assays; 1–24 h for cellular pathway modulation, per validated protocols.
  • Controls: Vehicle control (DMSO-matched), positive/negative pathway controls, and counter-screens for cytotoxicity or off‑target kinase activity.

Note: No synthetic reaction temperatures, catalysts, or yields are applicable. Refer to your assay SOPs and the SDS/CoA for item-specific guidance.

Safety and Handling

Safety information specific to this SKU is not fully provided in the Product Data and must be taken from the SDS.

  • GHS classification, signal word, H/P statements, and pictograms: Not specified for this item; refer to SDS.
  • Likely hazard profile (general for small-molecule research compounds): May cause irritation to skin/eyes/respiratory tract; avoid inhalation, ingestion, and contact. Handle as a compound of unknown toxicity.

Best practices (general laboratory guidance):

  • Engineering controls: Work in a certified chemical fume hood or ventilated enclosure when weighing and preparing solutions.
  • PPE: Lab coat, safety glasses or splash goggles, and appropriate chemically resistant gloves (e.g., disposable nitrile). Consider double-gloving for extended handling.
  • Weighing and solution prep: Minimize dust/aerosol formation; use antistatic weighing boats and slow airflow in balances. Cap DMSO stocks promptly to limit moisture uptake.
  • Incompatibilities: Strong oxidizers and strong acids/bases may degrade heteroaromatic pharmacophores; segregate accordingly. Avoid exposure to light and moisture if noted in CoA/SDS.
  • First aid (overview; defer to SDS):
    • Skin/eye contact: Rinse with water for ≥15 minutes; remove contaminated clothing; seek medical attention if irritation persists.
    • Inhalation: Move to fresh air; seek medical attention if symptoms occur.
    • Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.

Disposal: Follow institutional and local regulations for organic hazardous waste. Decontaminate surfaces with suitable organic solvent followed by detergent/water as permitted.

Solvent Selection

For Defactinib used as a bioactive screening compound, solvent choice is driven by assay compatibility and compound solubility.

  • Primary stock solvent (general best practice):
    • DMSO at 10–50 mM is typical for hydrophobic kinase inhibitors. Prepare under dry, inert conditions if long-term storage is anticipated.
  • Alternative organic solvents (general):
    • DMF or NMP for initial dissolution when DMSO is insufficient; subsequently dilute into DMSO or assay buffer with careful mixing.
  • Aqueous handling:
    • Direct aqueous solubility is usually limited. Prepare fresh working solutions by serially diluting a DMSO stock into buffer (e.g., PBS, HEPES) while keeping final DMSO ≤0.1–0.5% v/v to maintain cell compatibility (verify with your assay).
  • Surfactants and carriers:
    • Non-ionic surfactants (e.g., 0.01–0.05% Tween‑20 or Pluronic F‑127) or serum proteins can help maintain supersaturation and reduce adsorption; confirm assay tolerance.

Comparison (general guidance):

  • DMSO: Highest solvating power and assay ubiquity; potential cell stress above ~0.5–1%.
  • DMF/NMP: Useful for stock preparation; more cytotoxic and hygroscopic—avoid in final assay media.
  • Ethanol/Acetonitrile: May work for intermediate dilutions; compatibility varies with biology and plastics.

Item-specific solubility limits: Not specified for this item; refer to CoA/Spec Sheet.

Storage and Reconstitution
  • Storage conditions (as provided): Store at -80°C.
  • Shipping (as provided): Shipped with dry ice packs + cold packs to maintain low temperature during transit.

Reconstitution (general best practice):

  • Allow the sealed container to equilibrate to room temperature in a desiccator before opening to prevent condensation.
  • Prepare concentrated stocks in anhydrous DMSO (e.g., 10–50 mM). Mix thoroughly to ensure complete dissolution. If necessary, briefly sonicate or warm gently (≤37 °C). Do not overheat.
  • Aliquot into single-use volumes (e.g., 10–50 µL) in low‑bind tubes to avoid repeated freeze–thaw cycles and adsorption losses.

Storage of solutions:

  • DMSO stocks: Store at −20 to −80 °C, protected from light and moisture. Minimize headspace and use inert gas overlay if long-term storage is planned. Avoid more than 3–4 freeze–thaw cycles.
  • Aqueous working solutions: Prepare fresh just before use; stability in aqueous buffers is assay‑dependent and typically limited (hours to a day). Discard if precipitation or discoloration occurs.

Stability/shelf life: Not specified for this item; refer to CoA/Spec Sheet. Always defer to item-specific documentation for definitive guidance.

Structure and Identity

Defactinib (also known in the literature as VS‑6063; PF‑04554878) is a research-grade, small-molecule ligand supplied in Aladdin’s Moligand™ format for discovery and screening workflows.

  • Item identifiers (as provided for this product):
    • CAS: 1073154-85-4
    • InChIKey: 94006 (as provided in Product Data)
    • CID: 25117126
  • Structural class (literature/general):
    • Typically described as a kinase-targeted, heteroaromatic small molecule bearing multiple nitrogen heterocycles and an anilide/aryl motif consistent with ATP-competitive kinase inhibitors.
    • Commonly categorized as a focal adhesion kinase (FAK/PTK2) pathway probe in chemical biology.
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.

2D structural description (literature/general, qualitative):

  • A polycyclic, multi-heteroatom scaffold comprising fused and/or linked aromatic/heteroaromatic rings (nitrogen-rich), with substituents conferring kinase hinge-binding capability and selectivity. The framework is consistent with planar to moderately twisted aryl–heteroaryl connectivity, enabling H-bond donor/acceptor interactions within the ATP-binding pocket.

Note: For exact atom connectivity and stereochemical annotation used for this specific catalog lot, consult the CoA/Spec Sheet and SDS.

Synthetic Utility

Defactinib is a finished bioactive small molecule and is not generally employed as a reagent or intermediate in routine organic synthesis.

Context for medicinal chemistry (literature/general):

  • Can serve as a reference scaffold for designing FAK-targeted analogs, enabling exploration of hinge-binding elements, solvent-exposed vectors, and substituent effects that tune kinome selectivity and ADME properties.
  • Derivatization opportunities (conceptual):
    • Installation of solubilizing side chains on solvent-exposed positions to improve aqueous handling for biochemical assays.
    • Attachment of clickable tags (alkyne/azide) or affinity handles (biotin, photoactivatable groups) for chemoproteomics or target validation experiments.
  • SAR exploration:
    • Variation of heteroaryl donors/acceptors impacting ATP-site interactions and off-target kinases (e.g., PYK2). Docking and co-crystal structures, where available in the literature for FAK inhibitors, guide modifications.

If your objective is to use this scaffold as a starting point for analog synthesis, request structural documentation (CoA) and consider a custom route with protected intermediates rather than modifying the final compound directly.

Target Specificity

Only include details from Product Data. For this item, target/assay specificity data are not provided.

  • Target name, selectivity panel results, binding constants, and off-target profile: Not specified for this item; refer to CoA/Spec Sheet or your internal assay data.

General literature context (for planning only): Defactinib is commonly used as a focal adhesion kinase (FAK/PTK2) pathway probe in research; verify selectivity and potency in your specific assay system.

Foire aux questions

What is Moligand??
Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.
How should this product be stored?
Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 1073154-85-4, the molecular formula is C20H21F3N8O3S, and the molecular weight is 510.49 g/mol. InChIKey FWLMVFUGMHIOAA-UHFFFAOYSA-N.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Besoin d'aide pour choisir la qualité ?

Notre guide de sélection des qualités couvre la pureté, le statut du stabilisant et l'adéquation à l'application pour toutes les variantes de notre catalogue.

Voir le guide des qualités Moligand™ →

Souhaitez-vous que nous vous envoyions un message lorsque des réductions seront disponibles?

Me rappeler plus tard

Merci ! Veuillez vérifier votre boîte de réception e-mail pour confirmer.

Oups ! Les notifications sont désactivées.